Assessing the ED Stroke Patient for Disability - What Are the Pitfalls and How to Avoid Them?

December 2, 2020

The NIH Stroke Scale is beneficial when used correctly but is has its limitations. Relying entirely on the NIHSS will miss significant disability in a number of patients. Acute stroke care demands more than just an NIHSS assessment.

0 Comments

Tweet Share

What Lessons Have You Learned About Endovascular Therapy in COVID Patients and What Should We All Know?

December 2, 2020

Acute interventional management during the COVID pandemic requires a change of focus and practice. Challenges abound and danger exists at every decision point.

0 Comments

Tweet Share

Controversies in Prehospital Medicine: Choosing the Destination Medical Center for Stroke Patients

December 2, 2020

Once a stroke is suspected in the field, it stands to reason that the destination matters for the patient. But how much does it matter and where should patients be taken? Data meets politics in this compelling podcast.

0 Comments

Tweet Share

When Might You Use Heparin in the NeuroICU for a Stroke Patient?

December 2, 2020

Heparin in stroke remains controversial. Understanding the history and data and essential to mastering stroke care.

0 Comments

Tweet Share

Are the NNT and NNH for tPA Useful or Misleading in Acute Stroke Care?

December 2, 2020

Stroke treatment data are hard to interpret and can be misleading. A lot of misinformation has made its way into the literature and has confounded acute stroke care. Understanding NNT and NNH can help clinicians understand risks and benefits in a meaningful way.

0 Comments

Tweet Share

RSS

First Previous 1 2 3 4 5 6 7 8 9 10 Next

Sep 7

Why Is the Extended Window Controversial and What Happened With the FDA?

Haemin Go posted on 9/7/2021

Moderator: William A. Knight IV, MD, FACEP, FNCS
Other Participants: Stacie L. Demel, DO, PhD

The ECASS 3 trial was an RCT of IV-rtPA in the window of 3-4.5 hrs after onset of stroke symptoms. It was conducted in Europe. The European regulatory bodies have endorsed tPA for that window, but the FDA has not. Listen to two national experts in stroke discuss the trial and the meaning of the endorsement or lack thereof. This podcast is a must for acute stroke practitioners!

Podcast, ED First Patient Contact, Care Team, EM, Neuro, Nursing, Pharm, Stroke Team, Time From Stroke, 01_< 6 hrs, Topics, Controversies, Tx Approach, Types Of Content, Podcast, Testing, Triage & Disability Assessment, Care Team, EM, Neuro, Stroke Team, Fibrinolytic Therapy, Care Team, EM, Hosp Med, Neuro, Neurophys, Stroke Team, Diagnosis, IS, Topics, Controversies, EBM, IV Rx, Lytic Therapy, Standard Care, Treatments, Types of Content, Podcast, ICU & Critical Care, Care Team, Critical Care, Hosp Med, Neuro, Stroke Team, Topics, Bleeding, Controversies, EBM, Types of Content, Podcast, Content Types, Podcast

2 Comments

Tweet Share

2 Comments

2 comments on article "Why Is the Extended Window Controversial and What Happened With the FDA?"

Ken Milne

I watched the video on ECASS-III and you mentioned the controversy in this time window. However, there was no mention of Alper et al reanalysis in the BMJ_EBM that questioned the results? Can you comment? https://ebm.bmj.com/content/25/5/168

Ken Milne

Here was some of our feedback on Alper et al https://ebm.bmj.com/content/early/2020/08/10/bmjebm-2020-111517

Please login or register to post comments.

The New Standards for Prehospital Stroke Patient Destinations; the Dawn of a New Era in EMS